-
Familial hypercholesterolemia, a narrative review, part 2: diagnosis and screening
March 11, 2022FH 1: diagnosis and screening
-
HeartCast 5: practical approach to the treatment of HFrEF
February 23, 2022The fifth HeartCast: HFrEF management
-
HeartCast 4: practical approach to the treatment of HFrEF
February 9, 2022The fourth HeartCast: HFrEF management
-
Familial hypercholesterolemia, a narrative review, part 1: definition and burden
January 14, 2022FH 1: Definition and burden
-
HeartCast 3: practical approach to the treatment of HFrEF
January 11, 2022The third HeartCast: HFrEF management
-
At a Glance: Approach to Ticagrelor-induced Dyspnea
January 2, 2022Managing dyspnea induced by Ticagrelor
-
HeartCast 2: practical approach to the treatment of HFrEF
December 29, 2021The second HeartCast: HFrEF management
-
At a glance: preventing cardiovascular thrombotic event after ACS
December 21, 2021Ticagrelor in preventing post-ACS thrombotic events
-
HeartCast 1: practical approach to the treatment of HFrEF
December 15, 2021The first HeartCast: HFrEF management
-
Cardiopoint 13: Management of stage 1 hypertension in adults with low cardiovascular risk
September 25, 2021Stage 1 HTN in low risk patients
-
Cardiopoint 12: Two-Drug Combinations as First-Step Antihypertensive treatment
May 30, 2021Initial administration of two-drug combinations in HTN
-
Self-measured blood pressure monitoring at home
April 17, 2021What to teach the patients about recording their blood pressure themselves
-
Dual RAAS inhibition in the treatment of systolic heart failure; at a glance Part two: Eplerenone in the guidelines
April 7, 2021Latest guideline recommendations on the use of RAAS inhibitors in heart failure patients
-
Dual RAAS inhibition in the treatment of systolic heart failure; at a glace Part one: Eplerenone in the pipeline
April 6, 2021Latest pieces of evidence regarding the use of RAAS inhibitors in heart failure patients
-
CardioPoint (11): Antithrombotic therapy in patients with AF treated with OAC undergoing PCI
March 11, 2021Quick Review of ACC 2020 Expert Consensus Pathway of Antithrombotic Management
-
CardioPoint (10): The growing burden of cardiovascular diseases
February 2, 2021Emphasizing the importance of CVD prevention and management
-
What is new in the 2020 ESC Guideline for the diagnosis and management of Atrial Fibrillation
December 7, 2020Part Four: LSM, bleeding management, pregnancy, POAF, sex related differences
-
What is new in the 2020 ESC Guideline for the diagnosis and management of AF
December 3, 2020Part Three: Cardioversion, rhythm control, catheter ablation Long term anti arrhythmic drugs
-
Apixaban Hub (4)
November 27, 2020NOAC Choice
-
What is new in the 2020 ESC Guideline for the diagnosis and management of AF
November 3, 2020Part Two: Prevention of thromboembolic events Patients with AF and an ACS, PCI or CCS
-
At a glance; Place of FDC in CV outcomes
October 7, 2020Single-Pill Combination Therapy and CV Outcomes in HTN
-
What is new in the 2020 ESC Guideline for the diagnosis and management of AF
October 3, 2020Updated changes in AF ESC 2020 compared to previous Guidelines (Part one)
-
Apixaban Hub (3)
September 23, 2020Apixaban in Clinical Practice
-
CardioPoint (9): Once vs. twice-daily NOACs and adherence considerations
August 22, 2020A Brief Description on Practical Points in Anticoagulation
-
At a glance; FDC role in HTN Pharmacotherapy
August 9, 2020Fixed dose combination therapy in HTN Treatment
-
Guideline Made Easy
August 3, 2020Practical Guide for treatment of high blood cholesterol Part One
-
Apixaban Hub (2)
July 27, 2020Apixaban in the pipeline: landmark clinical trials
-
Apixaban Hub (1)
June 27, 2020When to use, when not to use & which dose?
-
At a glance; How dual pathway found its way into ESC guidelines?
June 7, 2020Rivaroxaban on board for CCS
-
CardioPoint (8): When to consider drug treatment in hypertension?
May 24, 2020A Brief Description on Practical Points in Cardiometabolic Field
-
Cardiac involvement in COVID-19 infection
May 3, 2020Cardiovascular complications of COVID-19
-
At a glance: ACEI and ARB in COVID-19 Era
March 19, 2020The challenge of to use or not to use ACEI/ARBs in patients with COVID-19
-
CardioPoint (7): Selecting appropriate NOAC
February 28, 2020A Brief Description on Practical Points in Anticoagulation
-
PCSK9 Inhibition from bench to bedside
February 3, 2020Part Four: The Lower, The Better
-
PCSK9 Inhibition from bench to bedside
January 3, 2020Part Three: PCSK9 Inhibitor in my practice
-
Guideline Made Easy
December 7, 2019Practical Guide for Treatment of High Blood Pressure (Part Three)
-
Guideline Made Easy
December 7, 2019Practical Guide for Treatment of High Blood Pressure (Part Two)
-
Guideline Made Easy
December 7, 2019Practical Guide for Treatment of High Blood Pressure (Part One)
-
PCSK9 Inhibition from bench to bedside
December 3, 2019Part Two: Clinical Trials
-
CardioPoint (6): Treatment Target & Goal for LDL-Cholesterol
November 29, 2019A Brief Description on Practical Points in Cardiometabolic Field
-
Guideline Made Easy
November 3, 2019Practical Guide for treatment of high blood cholesterol Part Three
-
PCSK9 Inhibition from bench to bedside
November 3, 2019Part One: A success story
-
CardioPoint (5): NOACs in CKD
October 23, 2019A Brief Description on Practical Points in Anticoagulation
-
Guideline Made Easy
October 3, 2019Practical Guide for treatment of high blood cholesterol Part Two
-
CardioPoint (4): Fixed-Dose Combination Pills in the Management of Hypertension
September 20, 2019A Brief Description on Practical Points in Cardiometabolic Field
-
CardioPoint (3): NOACs in Elderly
August 19, 2019A Brief Description on Practical Points in Anticoagulation
-
CardioPoint (2) – NOAC Monitoring, Do NOACs Need Monitoring?
June 19, 2019A Brief Description on Practical Points in Anticoagulation
-
CardioPoint (1):Statins-Who is eligible?-Which dose?
May 19, 2019A Brief Description on Practical Points in Cardiometabolic Field
Follow US
Copyright All rights reserved ©2021 Daily Cardiology Academy Team
Design By Tysiz